The Board consists of 9 Directors, brief biographies of whom are set out below.

David Evans BCom., CA, MBA (aged 44), Non-Executive Chairman
David has considerable expertise within the diagnostic industry. As financial director he was a key member of the team that floated Shield Diagnostics Group plc in 1993 and was chief executive officer responsible for the merger of Shield Diagnostics Group plc with Axis Biochemicals ASA of Norway in 1999 to create Axis-Shield plc. He is currently involved in a non-executive capacity with several other companies.

Roger Duggan PhD (aged 55), Managing Director
Roger joined RIA (UK), the forerunner of IDS in 1981. Within IDS, he has held the positions of development scientist, laboratory manager, and scientific director, becoming managing director following the management buy-out in 1996. Roger also sits on the
boards of PeriNatal Diagnostics Limited, PalindromX Limited, Pyrronostics Limited, Briefvision Limited, Phabia Limited and IDS Inc.

Paul Hailes FCCA (aged 41), Finance Director
Paul gained experience with Bowater plc and Courtaulds plc before joining IDS in February 1993. Paul is also a Director and/or Company Secretary in PeriNatal Diagnostics Limited, PalindromX Limited, Pyrronostics Limited, Briefvision Limited, Phabia Limited and the Subsidiary.

Anthony ‘Tony’ Wilks (aged 45) Sales and Marketing Director
Living for more than 20 years in Germany and with 18 years experience in European sales and marketing of diagnostic products. Tony brings a wealth of experience in international sales to IDS. Tony recently joined IDS from Nichols Institute Diagnostics GmbH, a wholly-owned subsidiary of European Operations. Tony had been with Nichols Institute since 1997. In 1990 Tony started Tosoh Medics GmbH in Germany and successfully established Tosoh as a major diagnostic company in immunoassay automation. Prior to this Tony was Product Manager for Oxford Medical Systems GmbH, responsible for cardiovascular system, marketing and distribution sales.

Martha brings 11 years of experience gained in senior appointments within the industry, and almost unique skills in the automation of immunoassays. Having graduated in Chemistry from the University of New Hampshire, Martha went on to gain a Doctorate in Organic Chemistry from the University of North Carolina in Chapel Hill.  She then became a Post-Doctoral Fellow in the Chemical Separations Group at the prestigious Oak Ridge National Laboratory, Tennessee.
Martha entered the commercial In Vitro Diagnostics industry, joining Nichols Institute Diagnostics (NID, San Clemente, California a subsidiary of Quest Diagnostics) in 1995 as a Senior R&D Scientist.  She became a key member of the team created to convert the well-established immunoassays of NID into fully-automated formats for the Nichols Advantage which was at that time a new and ground-breaking instrument targeted at medium-to-large throughput specialist laboratories.
In the ensuing years at NID, Martha became centrally involved in immunoassay automation, as Manager of R&D (1999-2002) and thereafter Associate Scientific Director, during which time she participated in, or presided over, the development of in the region of 20 automated products which were launched on the Advantage, and filed 6 patents relating to technology development.   

Christopher "Ian" Cookson, (aged 54), Operations Director
Ian brings more than 20 years of experience gained in senior appointments within the In Vitro Diagnostics (IVD) industry, and a skill set of particular relevance to the forward strategic plans of IDS. Mr Cookson joined IDS from Axis-Sheild plc, where he was Managing Director of their Dundee based Laboratory Division.
His experience will be particularly relevant to his position as Operations Director of IDS. With the licence agreement to the 3X3 instrument signed with Biocode-Hycel of Liege in December 2006, and the subsequent acquisition of the French/Belgian company in its entirety in August 2007, IDS has entered the realm of automated IVD. This represents a 'sea change' in the strategic development of IDS, and one that recent appointment with automation experience will relish.

Alain Rousseau (aged 57), Engineering Director
Alain gained his experience in both the High-tech sensors and Automative industries before turning his skills to the In-Vitro Diagnostics market. He has filed for over 30 patents in these areas over the course of his career. As Head of Instrumentation for Diagnostica Stago, he created and developed the production of the entire instrumentation product line.
Alain joined Biocode Hycel in mid 2003 as CEO, to develop a new innovative and multidisciplinary platform which is now the 3X3 Automated system. As part of the Biocode acquisition, Alain joins the IDS board to drive the manufacture and system design going forward.

William “Will” Dracup (aged 40), Non-Executive Director
Will founded Nonlinear Dynamics Limited in 1989. An Economics graduate and software engineer, Will became interested in the analysis of protein separations after working for a life science imaging 16 company, Joyce-Loebl Limited. Deciding that the available Technology was inadequate,Will went on to develop software that has since become the industry standard in its field. Nonlinear Dynamics Limited grew throughout the 1990’s, and Will has overseen the successful diversification of the company into the US and Asia Pacific markets, with the company’s product line growing into a wide range of application areas within life sciences.

Edward “Eddie” Blair PhD (aged 45), Non-Executive Director
Following a research career in virology at the MRC National Institute for Medical Research (Mill Hill, London) and University of California (Irvine CA, US), Eddie spent 15 years in the pharmaceutical industry and held the positions of programme leader in virology then later clinical therapeutic adviser to the Predictive Medicine Group, at GlaxoWellcome, before becoming a director of clinical diagnostics at GlaxoSmithKline plc. He is currently a director of Integrated Medicines Limited.